IL207632D0 - Compositions for enhanced uptake of viral vectors in the myocardium - Google Patents

Compositions for enhanced uptake of viral vectors in the myocardium

Info

Publication number
IL207632D0
IL207632D0 IL207632A IL20763210A IL207632D0 IL 207632 D0 IL207632 D0 IL 207632D0 IL 207632 A IL207632 A IL 207632A IL 20763210 A IL20763210 A IL 20763210A IL 207632 D0 IL207632 D0 IL 207632D0
Authority
IL
Israel
Prior art keywords
myocardium
compositions
viral vectors
enhanced uptake
uptake
Prior art date
Application number
IL207632A
Original Assignee
Celladon Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US2988108P priority Critical
Priority to PCT/US2008/081634 priority patent/WO2009105135A1/en
Application filed by Celladon Corp filed Critical Celladon Corp
Publication of IL207632D0 publication Critical patent/IL207632D0/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/04Nitro compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA Viruses
    • C12N2750/00011MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA Viruses ssDNA Viruses
    • C12N2750/14011Parvoviridae
    • C12N2750/14111Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA Viruses
    • C12N2750/00011MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA Viruses ssDNA Viruses
    • C12N2750/14011Parvoviridae
    • C12N2750/14111Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14171Demonstrated in vivo effect
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827Proteins from mammals or birds
    • Y10S530/841Muscles; heart
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00Nanotechnology
    • Y10S977/902Specified use of nanostructure
    • Y10S977/904Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/908Mechanical repair performed/surgical
    • Y10S977/913Stem cell therapy implantation
IL207632A 2008-02-19 2010-08-16 Compositions for enhanced uptake of viral vectors in the myocardium IL207632D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US2988108P true 2008-02-19 2008-02-19
PCT/US2008/081634 WO2009105135A1 (en) 2008-02-19 2008-10-29 Compositions for enhanced uptake of viral vectors in the myocardium

Publications (1)

Publication Number Publication Date
IL207632D0 true IL207632D0 (en) 2010-12-30

Family

ID=40293837

Family Applications (1)

Application Number Title Priority Date Filing Date
IL207632A IL207632D0 (en) 2008-02-19 2010-08-16 Compositions for enhanced uptake of viral vectors in the myocardium

Country Status (9)

Country Link
US (5) US8221738B2 (en)
EP (1) EP2244740A1 (en)
JP (1) JP2011512408A (en)
KR (1) KR20100129295A (en)
CN (1) CN101977632A (en)
AU (1) AU2008350903B2 (en)
CA (1) CA2715765A1 (en)
IL (1) IL207632D0 (en)
WO (1) WO2009105135A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2658628A1 (en) * 2006-07-25 2008-01-31 Celladon Corporation Extended antegrade epicardial coronary infusion of adeno-associated viral vectors for gene therapy
JP2011512408A (en) 2008-02-19 2011-04-21 セラドン・コーポレーション Composition for increasing viral vector uptake into the myocardium
US20120005045A1 (en) 2010-07-01 2012-01-05 Baker Scott T Comparing items using a displayed diagram

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5698531A (en) 1989-03-31 1997-12-16 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5661133B1 (en) 1991-11-12 1999-06-01 Univ Michigan Collateral blood vessel formation in cardiac muscle by injecting a dna sequence encoding an angiogenic protein
US5587308A (en) 1992-06-02 1996-12-24 The United States Of America As Represented By The Department Of Health & Human Services Modified adeno-associated virus vector capable of expression from a novel promoter
US6268213B1 (en) 1992-06-03 2001-07-31 Richard Jude Samulski Adeno-associated virus vector and cis-acting regulatory and promoter elements capable of expressing at least one gene and method of using same for gene therapy
AU694097B2 (en) 1992-11-18 1998-07-16 Arch Development Corporation Adenovirus-mediated gene transfer to cardiac and vascular smooth muscle
US5478745A (en) 1992-12-04 1995-12-26 University Of Pittsburgh Recombinant viral vector system
US6323184B1 (en) 1993-10-15 2001-11-27 Thomas Jefferson University Arteriovenous and venous graft treatments: methods and compositions
US5658785A (en) 1994-06-06 1997-08-19 Children's Hospital, Inc. Adeno-associated virus materials and methods
US5792453A (en) 1995-02-28 1998-08-11 The Regents Of The University Of California Gene transfer-mediated angiogenesis therapy
EP1255822A2 (en) 1999-12-27 2002-11-13 The Regents Of The University Of California Modified adenylylcyclase type vi useful in gene therapy for congestive heart failure
US6752987B1 (en) 1995-02-28 2004-06-22 The Regents Of The University Of California Adenovirus encoding human adenylylcyclase (AC) VI
US20030148968A1 (en) 1995-02-28 2003-08-07 Hammond H. Kirk Techniques and compositions for treating cardiovascular disease by in vivo gene delivery
EA001616B1 (en) 1995-02-28 2001-06-25 Зе Риджентс Оф Зи Юнивесити Оф Кэлифоньэ Method for treating a heart disease, method for treating a peripheral deficient vascular disease and method of limiting transgene delivery and expression to a single organ or structure
US20040132190A1 (en) 1995-02-28 2004-07-08 The Regents Of The University Of California Gene therapy for myocardial ischemia
US7745416B2 (en) 1995-04-11 2010-06-29 The Regents Of The University Of California Method for in vivo regulation of cardiac muscle contractility
US6605274B1 (en) 1995-04-11 2003-08-12 The Regents Of The University Of California Method for in vivo regulation of cardiac muscle contractility
US5773289A (en) 1995-06-06 1998-06-30 University Of Pittsburgh AAV directed targeted integration
CA2221710A1 (en) 1995-06-07 1996-12-19 The Regents Of The University Of California Gene therapy for myocardial ischemia
US5863904A (en) 1995-09-26 1999-01-26 The University Of Michigan Methods for treating cancers and restenosis with P21
US6162796A (en) 1995-09-27 2000-12-19 The Rockefeller University Method for transferring genes to the heart using AAV vectors
US20020001574A1 (en) 1995-12-13 2002-01-03 Jon A. Woiff Process of delivering a polynucleotide to a muscle cell via the vascular system
US20050222075A1 (en) 1998-09-14 2005-10-06 Hans Herweijer Process for delivering nucleic acids to cardiac tissue
US5846528A (en) 1996-01-18 1998-12-08 Avigen, Inc. Treating anemia using recombinant adeno-associated virus virions comprising an EPO DNA sequence
US5962313A (en) 1996-01-18 1999-10-05 Avigen, Inc. Adeno-associated virus vectors comprising a gene encoding a lyosomal enzyme
US5858351A (en) 1996-01-18 1999-01-12 Avigen, Inc. Methods for delivering DNA to muscle cells using recombinant adeno-associated virus vectors
CA2262406C (en) 1996-09-05 2010-12-07 The Regents Of The University Of California Gene therapy for congestive heart failure
US6306830B1 (en) 1996-09-05 2001-10-23 The Regents Of The University Of California Gene therapy for congestive heart failure
US6090618A (en) 1996-10-07 2000-07-18 Arch Development Corporation DNA constructs and viral vectors comprising a smooth muscle promoter
CA2287478C (en) 1997-04-14 2007-06-19 Richard J. Samulski Methods for increasing the efficiency of recombinant aav product
EA005157B1 (en) 1997-05-06 2004-12-30 Те Риджентс Оф Те Юниверсити Оф Калифорния Techniques and compositions for treating heart failure and ventricular remodeling by in vivo delivery of angiogenic transgenes
US6177272B1 (en) 1997-07-21 2001-01-23 The Regents Of The University Of Michigan Method for treating vascular proliferative diseases with p27 and fusions thereof
EP1374909A3 (en) 1997-07-22 2004-01-21 The General Hospital Corporation Evaluation of, delivery of, and use of agents to treat heart disorders
US20090239940A1 (en) 1997-07-22 2009-09-24 Del Monte Federica Treating heart failure and ventricular arrhythmias
US20050095227A1 (en) 1997-07-22 2005-05-05 The General Hospital Corporation Treating heart failure
WO1999018792A1 (en) 1997-10-10 1999-04-22 Johns Hopkins University Gene delivery compositions and methods
US6410300B1 (en) 1998-01-12 2002-06-25 The University Of North Carolina At Chapel Hill Methods and formulations for mediating adeno-associated virus (AAV) attachment and infection and methods for purifying AAV
KR20010015915A (en) 1998-02-11 2001-02-26 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 Combination of a nucleic acid and a vasoactive agent for enhanced gene delivery
US6126419A (en) * 1998-06-19 2000-10-03 Hansen; Jerry W. Caustic pumping apparatus
US6203991B1 (en) 1998-08-21 2001-03-20 The Regents Of The University Of Michigan Inhibition of smooth muscle cell migration by heme oxygenase I
US6770473B1 (en) 1998-08-21 2004-08-03 The Regents Of The University Of Michigan hKIS compositions and methods of use
ES2229788T3 (en) 1998-10-26 2005-04-16 Licentia Ltd. Use of the vegf-c or vegf-d gene or protein to prevent restenosis.
US6958147B1 (en) 1998-10-26 2005-10-25 Licentia Ltd Use of VEGF-C to prevent restenosis
CA2349758A1 (en) 1998-11-02 2000-05-11 The Regents Of The University Of California A method for inhibition of phospholamban activity for the treatment of cardiac disease and heart failure
US6759237B1 (en) 1998-11-05 2004-07-06 The Trustees Of The University Of Pennsylvania Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same
CA2349838C (en) 1998-11-05 2011-06-07 The Trustees Of The University Of Pennsylvania Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same
JP2002538770A (en) 1998-11-10 2002-11-19 ユニバーシティ オブ ノース カロライナ アット チャペル ヒル The method of its preparation and administered with a viral vector
EP1139751A4 (en) 1998-12-28 2003-03-19 Arch Dev Corp Efficient and stable $i(in vivo) gene transfer to cardiomyocytes using recombinant adeno-associated virus vectors
US7078387B1 (en) 1998-12-28 2006-07-18 Arch Development Corp. Efficient and stable in vivo gene transfer to cardiomyocytes using recombinant adeno-associated virus vectors
AU2001268149B2 (en) 2000-06-01 2005-08-18 University Of North Carolina At Chapel Hill Methods and compounds for controlled release of recombinant parvovirus vectors
AU6837301A (en) 2000-06-13 2001-12-24 Philadelphia Children Hospital Methods for administering recombinant adeno-associated virus virions to humans previously exposed to adeno-associated virus
US7034008B2 (en) 2000-09-06 2006-04-25 The Johns Hopkins University Cardiac arrhythmia treatment methods
EP1317289B1 (en) * 2000-09-11 2009-02-25 The Regents of the University of California Dominant negative PLB mutant for use in treating cardiac disease
JP2004534719A (en) 2000-10-13 2004-11-18 ジョンズ・ホプキンス・ユニバーシティ Methods and compositions for nucleic acid delivery
US20040009940A1 (en) 2000-10-20 2004-01-15 Coleman Michael E. Gene delivery formulations and methods for treatment of ischemic conditions
US20020159978A1 (en) 2001-02-06 2002-10-31 James Allen Muscle-directed gene transfer by use of recombinant AAV-1 and AAV-6 virions
CA2445578C (en) 2001-04-27 2012-08-28 Johns Hopkins University Biological pacemaker comprising dominant-negative kir2.1aaa
US20040106954A1 (en) 2002-11-15 2004-06-03 Whitehurst Todd K. Treatment of congestive heart failure
US7781415B2 (en) 2003-02-07 2010-08-24 Roche Madison Inc. Process for delivering sirna to cardiac muscle tissue
US20040214182A1 (en) 2003-04-25 2004-10-28 Vinod Sharma Genetic modification of targeted regions of the cardiac conduction system
US8007778B2 (en) 2003-07-01 2011-08-30 The Regents Of The University Of California Use of calcium binding proteins to improve cardiac contractile function
WO2005023292A1 (en) 2003-09-03 2005-03-17 The General Hospital Corporation Methods of treating restenosis
EP1691609A4 (en) 2003-12-11 2006-11-29 Mirus Bio Corp Delivery of viral vectors to extravascular parenchymal cells
US20060148742A1 (en) 2004-02-26 2006-07-06 Kaye David M Polynucleotide delivery to cardiac tissue
US7840263B2 (en) 2004-02-27 2010-11-23 Cardiac Pacemakers, Inc. Method and apparatus for device controlled gene expression
CA2658628A1 (en) * 2006-07-25 2008-01-31 Celladon Corporation Extended antegrade epicardial coronary infusion of adeno-associated viral vectors for gene therapy
US9375440B2 (en) 2006-11-03 2016-06-28 Medtronic, Inc. Compositions and methods for making therapies delivered by viral vectors reversible for safety and allele-specificity
JP2011512408A (en) * 2008-02-19 2011-04-21 セラドン・コーポレーション Composition for increasing viral vector uptake into the myocardium

Also Published As

Publication number Publication date
US20170312373A1 (en) 2017-11-02
AU2008350903B2 (en) 2015-04-02
US20160263248A1 (en) 2016-09-15
US8636998B2 (en) 2014-01-28
US20130109736A1 (en) 2013-05-02
US20140107191A1 (en) 2014-04-17
AU2008350903A1 (en) 2009-08-27
US8221738B2 (en) 2012-07-17
KR20100129295A (en) 2010-12-08
EP2244740A1 (en) 2010-11-03
WO2009105135A1 (en) 2009-08-27
CN101977632A (en) 2011-02-16
CA2715765A1 (en) 2009-08-27
JP2011512408A (en) 2011-04-21
US20090209631A1 (en) 2009-08-20

Similar Documents

Publication Publication Date Title
GB0820344D0 (en) Herbicidal compositions
EP2291728A4 (en) Virtual touchpad
PL2190965T3 (en) Detergent composition
PL2217690T3 (en) Detergent composition
EP2219637A4 (en) Avenanthramide-containing compositions
PL2283101T3 (en) Hydrofluoroolefin compositions
PL2283102T3 (en) Hydrofluoroolefin compositions
ZA201002668B (en) Detergent compositions
IL211147D0 (en) 1h-benzimidazole-5-carboxamides as anti-inflammatory agents
GB0812028D0 (en) Fungicidal compositions
HK1162378A1 (en) Tetrafluoropropene compositions and uses thereof
EP2310445A4 (en) Copolymer surfactants
ZA201005268B (en) Composition
EP2352706A4 (en) Reduced-carbon footprint concrete compositions
TWI455690B (en) Herbicidal compositions
ZA201005763B (en) Laundry treatment compositions
GB0724342D0 (en) Anitbacterial compositions
IL199656D0 (en) Tablet-in-tablet compositions
ZA201103926B (en) Stable sulfoximine-insecticide compositions
GB0805908D0 (en) Laundry treatment compositions
EP2572243A4 (en) Polymerizable composition
ZA201202118B (en) Detergent composition
PL2135932T3 (en) Laundry composition
PL3056214T3 (en) Novel adjuvant compositions
EP2246377A4 (en) Resin composition